These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 30900154)

  • 21. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis.
    Ji J; Yao Y; Guan F; Sun L; Zhang G
    J Cancer Res Ther; 2022 Dec; 18(7):1884-1893. PubMed ID: 36647946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis.
    Corsi NJ; Messing EM; Sood A; Keeley J; Bronkema C; Rakic N; Jamil M; Dalela D; Arora S; Piontkowski AJ; Majdalany SE; Butaney M; Rakic I; Li P; Menon M; Rogers CG; Abdollah F
    Clin Genitourin Cancer; 2022 Dec; 20(6):e498-e505. PubMed ID: 35871040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression.
    Chen MK; Qin ZK; Zhou FJ; Han H; Liu ZW; Li YH; Yao K; Hou GL; Ye YL; Zhang ZL; Tu H; Zhang XQ; Lu KS; Yang ZW
    J Chemother; 2009 Dec; 21(6):681-6. PubMed ID: 20071293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
    Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
    Igawa M; Urakami S; Shirakawa H; Shiina H; Ishibe T; Kadena H; Usui T; Kawanishi M
    Br J Urol; 1996 Mar; 77(3):358-62. PubMed ID: 8814838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
    Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.
    Onozawa M; Miyanaga N; Hinotsu S; Miyazaki J; Oikawa T; Kimura T; Takaoka E; Kawai K; Shimazui T; Sakurai H; Nishiyama H; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):825-30. PubMed ID: 22782963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.
    Chen S; Sun G; Chen X; Salgado T; Wu S; Hu H; Liu R; Qie Y
    BMC Urol; 2024 Jan; 24(1):25. PubMed ID: 38297256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
    Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
    Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence.
    Yap SA; Brunson A; Pugashetti N; Cress RD; Keegan THM; deVere White R; Wun T
    Urol Oncol; 2018 Nov; 36(11):498.e1-498.e7. PubMed ID: 30236855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.